Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

PubMed for Gene (Select 9947)

1.

Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?

Braga WM, da Silva BR, Alves VL, Bortoluzo AB, Atanackovic D, Colleoni GW.

Immunotherapy. 2014;6(5):569-75. doi: 10.2217/imt.14.24.

PMID:
24896625
2.

YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.

Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, Iizuka A, Kume A, Sugino T, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K.

Oncol Rep. 2014 Jul;32(1):159-66. doi: 10.3892/or.2014.3195. Epub 2014 May 16.

PMID:
24842123
3.

Sperm protein 17, MAGE-C1 and NY-ESO-1 in hepatocellular carcinoma: expression frequency and their correlation with clinical parameters.

Xia QY, Liu S, Li FQ, Huang WB, Shi LN, Zhou XJ.

Int J Clin Exp Pathol. 2013 Jul 15;6(8):1610-6. Print 2013.

4.

The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells.

Cox JL, Wilder PJ, Gilmore JM, Wuebben EL, Washburn MP, Rizzino A.

PLoS One. 2013 May 7;8(5):e62857. doi: 10.1371/journal.pone.0062857. Print 2013.

5.

Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.

Zimmermann AK, Imig J, Klar A, Renner C, Korol D, Fink D, Stadlmann S, Singer G, Knuth A, Moch H, Caduff R.

Virchows Arch. 2013 May;462(5):565-74. doi: 10.1007/s00428-013-1395-3. Epub 2013 Mar 26.

PMID:
23529156
6.

MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.

de Carvalho F, Alves VL, Braga WM, Xavier CV Jr, Colleoni GW.

Cancer Immunol Immunother. 2013 Jan;62(1):191-5. doi: 10.1007/s00262-012-1376-4. Epub 2012 Nov 22.

PMID:
23180015
7.

Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

de Carvalho F, Costa ET, Camargo AA, Gregorio JC, Masotti C, Andrade VC, Strauss BE, Caballero OL, Atanackovic D, Colleoni GW.

PLoS One. 2011;6(11):e27707. doi: 10.1371/journal.pone.0027707. Epub 2011 Nov 16.

8.

Exome sequencing supports a de novo mutational paradigm for schizophrenia.

Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S, Gogos JA, Karayiorgou M.

Nat Genet. 2011 Aug 7;43(9):864-8. doi: 10.1038/ng.902.

9.

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene.

Mattila H, Schindler M, Isotalo J, Ikonen T, Vihinen M, Oja H, Tammela TL, Wahlfors T, Schleutker J.

BMC Cancer. 2011 Aug 2;11:327. doi: 10.1186/1471-2407-11-327.

10.

Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.

Curioni-Fontecedro A, Nuber N, Mihic-Probst D, Seifert B, Soldini D, Dummer R, Knuth A, van den Broek M, Moch H.

PLoS One. 2011;6(6):e21418. doi: 10.1371/journal.pone.0021418. Epub 2011 Jun 27.

11.

Frequent MAGE mutations in human melanoma.

Caballero OL, Zhao Q, Rimoldi D, Stevenson BJ, Svobodová S, Devalle S, Röhrig UF, Pagotto A, Michielin O, Speiser D, Wolchok JD, Liu C, Pejovic T, Odunsi K, Brasseur F, Van den Eynde BJ, Old LJ, Lu X, Cebon J, Strausberg RL, Simpson AJ.

PLoS One. 2010 Sep 16;5(9). pii: e12773. doi: 10.1371/journal.pone.0012773. Erratum in: PLoS One. 2010;5(11). doi: 10.1371/annotation/3ee2788f-0c44-429f-85c3-d626c9fedc21.

12.

Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.

Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15187-92. doi: 10.1073/pnas.1002155107. Epub 2010 Aug 9.

13.

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.

Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A.

Exp Mol Pathol. 2010 Oct;89(2):175-81. doi: 10.1016/j.yexmp.2010.06.011. Epub 2010 Jul 14.

PMID:
20621094
14.

Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.

Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, Jayabalan D, Niesvizky R, Jagannath S, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ.

Cancer Immun. 2010 Jan 29;10:4.

15.

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.

Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander AR, Bokemeyer C, Kröger N.

Haematologica. 2010 May;95(5):785-93. doi: 10.3324/haematol.2009.014464. Epub 2009 Dec 16.

16.

Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.

Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA, Colleoni GW.

Cancer Immun. 2008 Feb 1;8:2.

17.

Toward a confocal subcellular atlas of the human proteome.

Barbe L, Lundberg E, Oksvold P, Stenius A, Lewin E, Björling E, Asplund A, Pontén F, Brismar H, Uhlén M, Andersson-Svahn H.

Mol Cell Proteomics. 2008 Mar;7(3):499-508. Epub 2007 Nov 19.

18.

Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility.

Krüger S, Ola V, Feller AC, Fischer D, Friedrich M.

Pathol Oncol Res. 2007;13(2):91-6. Epub 2007 Jul 3.

19.

Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6).

Cho HJ, Caballero OL, Gnjatic S, Andrade VC, Colleoni GW, Vettore AL, Outtz HH, Fortunato S, Altorki N, Ferrera CA, Chua R, Jungbluth AA, Chen YT, Old LJ, Simpson AJ.

Cancer Immun. 2006 Dec 1;6:12.

20.

Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.

Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, Yamamoto J, Sekine M, Tsuritani K, Wakaguri H, Ishii S, Sugiyama T, Saito K, Isono Y, Irie R, Kushida N, Yoneyama T, Otsuka R, Kanda K, Yokoi T, Kondo H, Wagatsuma M, Murakawa K, Ishida S, Ishibashi T, Takahashi-Fujii A, Tanase T, Nagai K, Kikuchi H, Nakai K, Isogai T, Sugano S.

Genome Res. 2006 Jan;16(1):55-65. Epub 2005 Dec 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk